Patents by Inventor John McNeill McGill

John McNeill McGill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR ADMINISTERING GLP-1 MOLECULES
    Publication number: 20150202296
    Abstract: The invention relates to formulations that demonstrate the feasibility of oral absorption comprising glucose-like peptide-1 compounds and specified delivery agents, and to methods of stimulating GLP-1 receptor in a subject in need of such stimulation, by administration of the formulation of the present invention.
    Type: Application
    Filed: January 22, 2015
    Publication date: July 23, 2015
    Inventors: Mohammed Amin KHAN, Bryan Edward Jones, John Mcneill McGill
  • COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MIC4) AGONIST PEPTIDE
    Publication number: 20140031287
    Abstract: The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
    Type: Application
    Filed: August 20, 2013
    Publication date: January 30, 2014
    Applicant: Emisphere Technologies, Inc.
    Inventors: Robert Jason Herr, Louis Nickolaus Jungheim, John McNeill McGill, Kenneth Jeff Thrasher, Muralikrishna Valluri
  • METHOD FOR ADMINISTERING GLP-1 MOLECULES
    Publication number: 20140005106
    Abstract: The invention relates to formulations that demonstrate the feasibility of oral absorption comprising glucose-like peptide-1 compounds and specified delivery agents, and to methods of stimulating GLP-1 receptor in a subject in need of such stimulation, by administration of the formulation of the present invention.
    Type: Application
    Filed: July 16, 2013
    Publication date: January 2, 2014
    Applicant: Emisphere Technologies, Inc.
    Inventors: Mohammed Amin KHAN, Bryan Edward Jones, John Mcneill McGill
  • Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (Glp)-1 compound or a melanocortin-4 receptor (Mc4) agonist peptide
    Patent number: 8546581
    Abstract: The present application relates to novel compounds, methods and formulations useful for the oral delivery of a glucagon like peptide-1 compound or a melanocortin 4 receptor agonist peptide.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: October 1, 2013
    Assignee: Emisphere Technologies, Inc.
    Inventors: Louis Nickolaus Jungheim, John Mcneill McGill, III, Kenneth Jeff Thrasher, Robert Jason Herr, Muralikrishna Valluri
  • Formulation comprising GLP-1
    Patent number: 8492330
    Abstract: The invention relates to formulations that demonstrate the feasibility of oral absorption comprising glucose-like peptide-1 compounds and specified delivery agents, and to methods of stimulating GLP-1 receptor in a subject in need of such stimulation, by administration of the formulation of the present invention.
    Type: Grant
    Filed: January 12, 2011
    Date of Patent: July 23, 2013
    Assignee: Emisphere Technologies, Inc.
    Inventors: Mohammed Amin Khan, Bryan Edward Jones, John McNeill McGill
  • Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide
    Publication number: 20110190205
    Abstract: The present application relates to novel compounds, methods and formulations useful for the oral delivery of a glucagon like peptide-1 compound or a melanocortin 4 receptor agonist peptide.
    Type: Application
    Filed: April 14, 2011
    Publication date: August 4, 2011
    Applicant: Emisphere Technologies, Inc.
    Inventors: Louis Nickolaus JUNGHEIM, John McNeill MCGILL, III, Kenneth Jeff THRASHER, Robert Jason HERR, Muralikrishna VALLURI
  • Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP)-1 compound or a melanocortin-4 receptor (MC4) agonist peptide
    Patent number: 7947841
    Abstract: The present application relates to novel compounds, methods and formulations useful for the oral delivery of a glucagon like peptide-1 compound or a melanocortin 4 receptor agonist peptide.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: May 24, 2011
    Assignee: Emisphere Technologies, Inc.
    Inventors: Louis Nickolaus Jungheim, John McNeill McGill, III, Kenneth Jeff Thrasher, Robert Jason Herr, Valluri Muralikrishna
  • Method for administering GLP-1 molecules
    Patent number: 7939494
    Abstract: The invention relates to formulations that demonstrate the feasibility of oral absorption comprising glucose-like peptide-1 compounds and specified delivery agents, and to methods of stimulating GLP-1 receptor in a subject in need of such stimulation, by administration of the formulation of the present invention.
    Type: Grant
    Filed: April 9, 2009
    Date of Patent: May 10, 2011
    Assignee: Emisphere Technologies, Inc.
    Inventors: Mohammed Amin Khan, Bryan Edward Jones, John McNeill McGill
  • COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MC4) AGONIST PEPTIDE
    Publication number: 20100120876
    Abstract: The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
    Type: Application
    Filed: December 11, 2009
    Publication date: May 13, 2010
    Applicant: EMISPHERE TECHNOLOGIES, INC.
    Inventors: Robert Jason HERR, Louis Nickolaus JUNGHEIM, John McNeill MCGILL, III, Kenneth Jeff THRASHER, Muralikrishna VALLURI
  • Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP)-1 compound or a melanocortin-4 receptor (MC4) agonist peptide
    Patent number: 7662771
    Abstract: The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
    Type: Grant
    Filed: August 18, 2004
    Date of Patent: February 16, 2010
    Assignee: Emisphere Technologies, Inc.
    Inventors: Robert Jason Herr, Louis Nickolaus Jungheim, John McNeill McGill, III, Kenneth Jeff Thrasher, Muralikrishna Valluri
  • METHOD FOR ADMINISTERING GLP-1 MOLECULES
    Publication number: 20090286735
    Abstract: The invention relates to formulations that demonstrate the feasibility of oral absorption comprising glucose-like peptide-1 compounds and specified delivery agents, and to methods of stimulating GLP-1 receptor in a subject in need of such stimulation, by administration of the formulation of the present invention.
    Type: Application
    Filed: April 9, 2009
    Publication date: November 19, 2009
    Inventors: Mohammed Amin Khan, Bryan Edward Jones, John McNeill McGill
  • Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide
    Publication number: 20090239798
    Abstract: The present application relates to novel compounds, methods and formulations useful for the oral delivery of a glucagon like peptide-1 compound or a melanocortin 4 receptor agonist peptide.
    Type: Application
    Filed: November 3, 2008
    Publication date: September 24, 2009
    Applicant: Emisphere Technologies, Inc.
    Inventors: Louis Nickolaus Jungheim, John McNeill McGill, III, Kenneth Jeff Thrasher, Robert Jason Herr, Muralikrishna Valluri
  • Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide
    Publication number: 20080214448
    Abstract: The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
    Type: Application
    Filed: August 18, 2004
    Publication date: September 4, 2008
    Applicant: EMISPHERE TECHNOLOGIES INC.
    Inventors: Robert Jason Herr, Louis Nickolaus Jungheim, John McNeill McGill, Kenneth Jeff Thrasher, Muralikrishna Valluri
  • Substituted tricyclics
    Patent number: 6713645
    Abstract: A class of novel tricyclics is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: March 30, 2004
    Assignee: Eli Lilly and Company
    Inventors: Nicholas James Bach, Susan Elizabeth Draheim, Robert Delane Dillard, Edward David Mihelich, Jason Scott Sawyer, Douglas Wade Beight, Michael LeRoy Phillips, Tulio Suarez, Daniel Jon Sall, Jolie Anne Bastian, Michael Lyle Denney, Gary Alan Hite, Michael Dean Kinnick, Robert Theodore Vasileff, John Michael Morin, Jr., Ho-Shen Lin, Michael Enrico Richett, Richard Waltz Harper, John McNeill McGill, III, Benjamin Alan Anderson, Nancy Kay Harn, Richard James Loncharich, Richard Walter Schevitz
  • Synthesis of 3-[4-(2-aminoethoxy)-benzoyl]-2-aryl-6-hydroxybenzo[b]thiophenes
    Patent number: 6472531
    Abstract: The present invention is directed to chemical processes for preparing 2-aryl-6-hydroxy-3-[4-(2-aminoethoxy)benzoyl]benzo[b]-thiophenes. The present invention is also directed to crystalline solvates and a non-solvated crystalline form of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]-benzo[b]thiophene hydrochloride, as well as processes for their preparation.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 29, 2002
    Assignee: Eli Lilly and Company
    Inventors: Elizabeth Smith LaBell, John McNeill McGill, Randal Scot Miller
  • Synthesis of 3-[4-(2-aminoethoxy)-benzoyl]-2-aryl-6-hydroxybenzo[b]thiophenes
    Patent number: 6399778
    Abstract: The present invention is directed to chemical processes for preparing 2-aryl-6-hydroxy-3-[4-(2-aminoethoxy)benzoyl]benzo[b]-thiophenes. The present invention is also directed to crystalline solvates and a non-solvated crystalline form of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]-benzo[b]thiophene hydrochloride, as well as processes for their preparation.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: June 4, 2002
    Assignee: Eli Lilly and Company
    Inventors: Elizabeth Smith LaBell, John McNeill McGill, Randal Scot Miller
  • Substituted tricyclics
    Patent number: 6177440
    Abstract: A class of novel tricyclics is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.
    Type: Grant
    Filed: April 21, 1998
    Date of Patent: January 23, 2001
    Assignee: Eli Lilly and Company
    Inventors: Nicholas James Bach, Susan Elizabeth Draheim, Robert Delane Dillard, Edward David Mihelich, Jason Scott Sawyer, Douglas Wade Beight, Michael LeRoy Phillips, Tulio Suarez, Daniel Jon Sall, Jolie Anne Bastian, Michael Lyle Denney, Gary Alan Hite, Michael Dean Kinnick, Robert Theodore Vasileff, John Michael Morin, Jr., Ho-Shen Lin, Michael Enrico Richett, Richard Waltz Harper, John McNeill McGill, III, Benjamin Alan Anderson, Nancy Kay Harn, Richard James Loncharich, Richard Walter Schevitz
  • Processes for preparing benzothiophenes
    Patent number: 6090949
    Abstract: The present invention relates to intermediates and processes for preparing benzothiophenes.
    Type: Grant
    Filed: April 29, 1998
    Date of Patent: July 18, 2000
    Assignee: Eli Lilly and Company
    Inventors: John McNeill McGill, III, Jerry Wayne Misner, Tony Yantao Zhang
  • Regioselective alkylation process for preparing substituted benzo[b]thiophenes
    Patent number: 6025495
    Abstract: The present invention provides processes for the regioselective alkylation of benzothiophenes.
    Type: Grant
    Filed: April 29, 1998
    Date of Patent: February 15, 2000
    Assignee: Eli Lilly and Company
    Inventors: John McNeill McGill, III, Randal Scott Miller